3 August 2020 - Goldman Sachs expects the Food and Drug Administration to approve at least one coronavirus vaccine this year. That would allow "large shares" of the U.S. population to get inoculated by July of next year, according to the investment bank.

"While highly uncertain, our baseline expectation is that a large number of vaccines eventually gain approval with at least one FDA approval this year," Daan Struyven, a senior economist at Goldman, told investors in a report on Monday.

Drugmakers have 26 vaccines in clinical trials, he noted. Among the candidates are a dozen that have reached Phase II trials and six that are in Phase III undergoing tests for large-scale efficacy and safety. For Europeans, U.S. regulatory approval of an initial vaccine would allow them to get vaccinated by October.

Read CBS News article